文献速递脊柱外科创伤骨科骨质疏松与代谢性骨病

亚急性脊髓损伤患者停用地舒单抗1年后下肢骨密度丢失

Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury.
PubMed 文献 · Osteoporos Int · 2023-02-03

研究纳入14例亚急性脊髓损伤患者(地舒单抗60mg组8例、安慰剂组6例),在基线和6、12个月给药,18个月主要终点完成后继续随访12个月。停用地舒单抗后12个月,髋部和膝部各区域平均骨密度百分比下降在两组间相似,但30个月时地舒单抗组膝部区域平均骨密度绝对值仍显著高于安慰剂组。

要点

  • 停用地舒单抗后12个月,髋部和膝部各区域平均骨密度百分比下降在两组间相似。
  • 30个月时地舒单抗组膝部区域平均骨密度绝对值仍显著高于安慰剂组。
  • 作者强调需进一步研究亚急性脊髓损伤后继续给予地舒单抗以避免脱矿。

核心结论

  • 在亚急性损伤期开始地舒单抗并维持治疗1年的脊髓损伤患者中,停药后平均骨密度百分比丢失与安慰剂组相似。
  • 随访12个月时膝部区域平均骨密度绝对值在地舒单抗组显著高于安慰剂组。

研究设计与样本

  • 研究为随机双盲安慰剂对照药物试验完成后的随访观察,共14例完成母研究的亚急性脊髓损伤患者。
  • 母研究方案为地舒单抗60mg(Prolia,Amgen Inc.,n=8)或安慰剂(n=6),在基线、6个月和12个月给药。
  • 在基线后18个月主要终点完成后继续随访12个月,采用双能X线吸收法测量总髋、股骨远端骨骺(DFE)、股骨远端干骺端(DFM)和胫骨近端骨骺(PTE)骨密度。

主要发现

  • 从18个月到30个月,髋部和膝部所有区域平均骨密度百分比下降在地舒单抗组和安慰剂组相似。
  • 30个月时,地舒单抗组平均骨密度绝对值在DFM(p=0.03)、DFE(p=0.04)和PTE(p=0.05)仍显著高于安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文强调需要额外试验来了解亚急性脊髓损伤后继续给予地舒单抗以避免脱矿的效果。
  • 原文强调需要研究亚急性脊髓损伤后继续给予地舒单抗以避免停药后病变下方骨骼明显脱矿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Twelve months following discontinuation of denosumab, the percent decrease in mean bone mineral density (BMD) values at the hip and knee regions were similar between both the denosumab and placebo groups. These findings emphasize the need for additional trials to understand the effect of continued administration of denosumab after subacute spinal cord injury (SCI) to avoid this demineralization. OBJECTIVE: To determine changes in BMD 1 year after denosumab was discontinued in participants with subacute SCI who had drug treatment initiated within 90 days post SCI and continued for 1 year. METHODS: Fourteen participants who completed a randomized, double-blinded, placebo-controlled drug trial (parent study: denosumab 60 mg (Prolia, Amgen Inc., n = 8) or placebo (n = 6); administered at baseline, 6, and 12 months) were followed 12 months after the 18 months from baseline primary end point was completed. The BMD of skeletal regions below the SCI at higher risk of fracture was measured [total hip, distal femur epiphysis (DFE), distal femur metaphysis (DFM), and proximal tibia epiphysis (PTE)] by dual energy X-ray absorptiometry. RESULTS: The percent decreases in mean BMD values at all regions of the hip and knee from 18 to 30 months were similar in both the denosumab and placebo groups. However, at 30 months, the absolute values for mean BMD remained significantly higher in the drug treatment than that of the placebo group at the DFM (p = 0.03), DFE (p = 0.04), and PTE (p = 0.05). CONCLUSIONS: In persons with SCI who initiated denosumab treatment during the subacute injury phase and maintained treatment for 1 year, the discontinuation of drug resulted in percent loss of mean BMD similar to that of the placebo group, with absolute mean BMD values at the knee regions at the 12-month follow-up visit significantly higher in the drug treatment than those in the placebo group. These data underscore the need to study continued administration of denosumab after subacute SCI to avoid marked demineralization in the sublesional skeleton upon discontinuation of this agent.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cirnigliaro CM, La Fountaine MF, Parrott JS, et al. Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury. Osteoporos Int. 2023. PMID: 36735054. doi:10.1007/s00198-023-06679-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。